Colossal Biosciences Raises $200M to Advance De-Extinction Efforts

The biotech company aims to revive extinct species like the woolly mammoth, dodo, and Tasmanian tiger while driving innovations in genetic engineering and conservation.

Colossal Biosciences has secured $200 million in Series C funding, bringing its total funding to $435 million and its valuation to $10.2 billion.
The company is developing genetic engineering technologies to recreate extinct species, with progress reported in projects for the woolly mammoth, dodo, and Tasmanian tiger.
Recent breakthroughs include creating high-quality ancient genomes, pioneering stem cell techniques, and advancing genome editing for species-specific traits.
Critics question the ethical implications, potential ecological impacts, and the feasibility of reintroducing these species into modern ecosystems.
Colossal is also using its technologies to support conservation efforts for endangered species, including rhinos, elephants, and threatened bird populations.